A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults ≥60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics
- Sponsors GSK
- 04 Oct 2024 Status changed from not yet recruiting to recruiting.
- 03 Oct 2024 New trial record